You are here:--Making Safety a Part of Drug Design

Making Safety a Part of Drug Design


Speaker: Claire Sadler, Senior Toxicologist, ApconiX, UK

Moderator: Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria

* This presentation was also part of the GARDP and CARB-X co-organized session ‘Antibiotic Bootcamps for Developers: Preclinical Toxicology’ at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance *

In this webinar, Claire Sadler discussed the toxicological challenges and pitfalls of antibiotic discovery programs. Potential safety risks are the major reason for terminating a program in early phases of antibiotic drug development. This webinar will help identifying the most common toxicology risks associated with antibiotic discovery and discuss potential mitigating strategies.


We hosted this live webinar with Claire Sadler and Ursula Theuretzbacher on 13 November 2018.

If you have questions or comments, please let us know. Do so by posting them in our forum or submitting them via the ‘Talk to an expert’ feature. You can also send questions to: info.revive@dndi.org.

2018-11-14T15:38:08+00:00